KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Regeneron Pharmaceuticals (REGN) Invested Capital (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 17 years of Invested Capital data on record, last reported at $32.0 billion in Q4 2025.

  • For Q4 2025, Invested Capital rose 2.04% year-over-year to $32.0 billion; the TTM value through Dec 2025 reached $32.0 billion, up 2.04%, while the annual FY2025 figure was $32.0 billion, 2.04% up from the prior year.
  • Invested Capital reached $32.0 billion in Q4 2025 per REGN's latest filing, up from $31.0 billion in the prior quarter.
  • Across five years, Invested Capital topped out at $32.0 billion in Q4 2025 and bottomed at $740.0 million in Q3 2021.
  • Average Invested Capital over 5 years is $23.0 billion, with a median of $24.9 billion recorded in 2023.
  • Peak YoY movement for Invested Capital: rose 0.04% in 2022, then skyrocketed 3264.1% in 2023.
  • A 5-year view of Invested Capital shows it stood at $740.0 million in 2021, then skyrocketed by 3230.46% to $24.6 billion in 2022, then increased by 13.43% to $28.0 billion in 2023, then rose by 12.1% to $31.3 billion in 2024, then increased by 2.04% to $32.0 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Invested Capital were $32.0 billion in Q4 2025, $31.0 billion in Q3 2025, and $29.9 billion in Q2 2025.